Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study.

IF 2.5 Q2 CLINICAL NEUROLOGY Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-02-29 eCollection Date: 2024-01-01 DOI:10.1177/20552173241233952

Jérôme de Seze, Christine Clerc, Matthieu Béreau, Bertrand Bourre, Hélène Zephir, Nicolas Collongues, Laurent Kremer, Patrick Vermersch, Kevin Bigaut

{"title":"Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study.","authors":"Jérôme de Seze, Christine Clerc, Matthieu Béreau, Bertrand Bourre, Hélène Zephir, Nicolas Collongues, Laurent Kremer, Patrick Vermersch, Kevin Bigaut","doi":"10.1177/20552173241233952","DOIUrl":null,"url":null,"abstract":"Objective: To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder.Methods: We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests.Results: The mean Timed-25-Foot Walk score was reduced from 14.8 (±2.4) to 11.3 (±1.9) seconds (p = 0.01). The mean score on the 12-item Multiple Sclerosis Walking Scale was reduced from 41.2 (±3.5) to 31.4 (±3.2) (p = 0.004).Conclusion: Dalfampridine seems to be useful for symptomatic treatment of walking impairment in neuromyelitis optica spectrum disorder.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908237/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20552173241233952","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder.

Methods: We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests.

Results: The mean Timed-25-Foot Walk score was reduced from 14.8 (±2.4) to 11.3 (±1.9) seconds (p = 0.01). The mean score on the 12-item Multiple Sclerosis Walking Scale was reduced from 41.2 (±3.5) to 31.4 (±3.2) (p = 0.004).

Conclusion: Dalfampridine seems to be useful for symptomatic treatment of walking impairment in neuromyelitis optica spectrum disorder.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

达福普啶对神经脊髓炎视网膜频谱障碍的疗效：试点研究

目的：评估达尔福林对神经脊髓炎视谱系障碍患者的疗效：评估达尔福林对神经脊髓炎视网膜频谱障碍患者的疗效：我们连续收治了15名患者，他们开始接受达法瑞汀治疗，每天两次，每次10毫克，疗程2周。疗效评估基于使用定时-25 英尺步行和 12 项多发性硬化步行量表测试的步行能力改善情况：结果：计时-25 英尺步行的平均得分从 14.8 秒（±2.4）降至 11.3 秒（±1.9）（p = 0.01）。12项多发性硬化症步行量表的平均得分从41.2（±3.5）分降至31.4（±3.2）分（p = 0.004）：结论：达尔福林似乎可用于神经脊髓炎视网膜频谱障碍患者行走障碍的对症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊